Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Holen · SciRah

Researcher profile · Semantic Scholar

K. Holen

Share profile

K. Holen — researcher profile on SciRah

h-index: 35
Works: 157
Citations: 4,977

Most-cited papers

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
S. Lubner, M. Mahoney, J. Kolesar, N. Loconte +9 more
2010Journal of Clinical Oncology258 citations Open access
Semantic Scholar
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
M. J. van den Bent, Gan K. Hui, A. Lassman, P. Kumthekar +20 more
2017Cancer Chemotherapy and Pharmacology126 citations Open access
Semantic Scholar
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
D. Reardon, A. Lassman, M. J. van den Bent, P. Kumthekar +14 more
2016Neuro-Oncology108 citations Open access
Semantic Scholar
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
A. Lassman, M. J. van den Bent, Gan K. Hui, D. Reardon +20 more
2018Neuro-Oncology104 citations Open access
Semantic Scholar
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
M. Mehta, Ding Wang, Fen Wang, L. Kleinberg +13 more
2015Journal of Neuro-Oncology102 citations
Semantic Scholar
A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma
T. Mohammed, K. Holen, R. Jaskula-Sztul, D. Mulkerin +5 more
2011The Oncologist86 citations Open access
Semantic Scholar
Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
P. Chabot, T. Hsia, J. Ryu, V. Gorbunova +10 more
2016Journal of Neuro-Oncology84 citations Open access
Semantic Scholar
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer
V. Chung, E. Heath, W. Schelman, Brendan Johnson +5 more
2012Cancer Chemotherapy and Pharmacology84 citations
Semantic Scholar
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
J. Cleary, C. R. Lima, H. Hurwitz, A. Montero +8 more
2014Investigational new drugs80 citations
Semantic Scholar
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma
Gan K. Hui, D. Reardon, A. Lassman, R. Merrell +16 more
2018Neuro-Oncology77 citations Open access
Semantic Scholar
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
K. Holen, C. Belani, G. Wilding, S. Ramalingam +7 more
2010Cancer Chemotherapy and Pharmacology75 citations Open access
Semantic Scholar
Phase 2 Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer
P. Philip, M. Mahoney, K. Holen, D. Northfelt +4 more
2011Cancer74 citations Open access
Semantic Scholar
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
George P. Kim, M. Mahoney, D. Szydlo, T. Mok +10 more
2010Investigational new drugs68 citations Open access
Semantic Scholar
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
A. Tolcher, P. LoRusso, Jennifer Arzt, T. Busman +6 more
2015Cancer Chemotherapy and Pharmacology66 citations
Semantic Scholar
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
B. Czito, D. Deming, G. Jameson, M. Mulcahy +11 more
2017The Lancet Gastroenterology and Hepatology63 citations
Semantic Scholar
Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
G. Goss, E. Vokes, M. Gordon, L. Gandhi +15 more
2018Cancer56 citations Open access
Semantic Scholar
A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors
K. Holen, R. DiPaola, Glenn Liu, A. Tan +7 more
2011Investigational new drugs55 citations Open access
Semantic Scholar
Population Pharmacokinetics of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (Triapine®) in Cancer Patients
J. Kolesar, R. Brundage, M. Pomplun, D. Alberti +4 more
2010Cancer Chemotherapy and Pharmacology49 citations Open access
Semantic Scholar
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
N. Jin, S. Lubner, D. Mulkerin, S. Rajguru +4 more
2016The Oncologist44 citations Open access
Semantic Scholar
A Multicenter Phase 1 Study of γ -secretase inhibitor RO4929097 in Combination with Capecitabine in Refractory Solid Tumors
N. Loconte, A. Razak, P. Ivy, Amye J. Tevaarwerk +11 more
2014Investigational new drugs43 citations Open access
Semantic Scholar
A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
M. Shah, D. Power, H. Kindler, K. Holen +6 more
2011Investigational new drugs43 citations
Semantic Scholar
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
A. Tolcher, P. LoRusso, Jennifer Arzt, T. Busman +7 more
2015Cancer Chemotherapy and Pharmacology41 citations
Semantic Scholar
A phase 1 study of ABT-806 in subjects with advanced solid tumors
J. Cleary, D. Reardon, N. Azad, L. Gandhi +11 more
2015Investigational new drugs33 citations
Semantic Scholar
Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
A. Lassman, L. Roberts-Rapp, I. Sokolova, Minghao Song +15 more
2019Clinical Cancer Research32 citations Open access
Semantic Scholar
A Phase I Study of Vorinostat in Combination with Bortezomib in Patients with Advanced Malignancies
W. Schelman, A. Traynor, K. Holen, J. Kolesar +13 more
2013Investigational new drugs28 citations Open access
Semantic Scholar
A Pre-Clinical and Clinical Study of Lithium in Low-Grade Neuroendocrine Tumors
S. Lubner, M. Kunnimalaiyaan, K. Holen, L. Ning +5 more
2011The Oncologist25 citations Open access
Semantic Scholar
A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.
D. Frank, A. Jumonville, N. Loconte, W. Schelman +10 more
2012Journal of Gastrointestinal Oncology24 citations
Semantic Scholar
Amongst eligible patients, age and comorbidity do not predict for dose limiting toxicity from phase I chemotherapy
N. Loconte, Maureen A. Smith, D. Alberti, J. Bozeman +5 more
2009Cancer Chemotherapy and Pharmacology24 citations Open access
Semantic Scholar
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
Gan K. Hui, L. Fichtel, A. Lassman, R. Merrell +14 more
201423 citations
Semantic Scholar
A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
Gan K. Hui, M. Burge, B. Solomon, Sze T. Lee +12 more
2021Journal of Nuclear Medicine22 citations Open access
Semantic Scholar
Phase 1 study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors
E. Lam, S. Eckhardt, W. Messersmith, A. Jimeno +13 more
2017Molecular Cancer Therapeutics21 citations Open access
Semantic Scholar
Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.
H. Xiong, R. Pradhan, A. Nada, A. Krivoshik +5 more
2014Anticancer Research20 citations
Semantic Scholar
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
Brian S. Choi, D. Alberti, W. Schelman, Jill M. Kolesar +6 more
2010Cancer Chemotherapy and Pharmacology19 citations Open access
Semantic Scholar
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
Gan K. Hui, K. Papadopoulos, L. Fichtel, A. Lassman +16 more
201518 citations
Semantic Scholar
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors
S. Ray, V. Bonthapally, K. Holen, G. Gauthier +3 more
2013Journal of Medical Economics14 citations
Semantic Scholar
Adjuvant therapy for colon cancer.
K. Holen, L. Saltz
2010Surgical Oncology Clinics of North America14 citations
Semantic Scholar
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
M. J. van den Bent, Gan K. Hui, A. Lassman, P. Kumthekar +16 more
201613 citations
Semantic Scholar
Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT‐263), a dual inhibitor of Bcl‐2 and Bcl‐XL, in patients with cancer
Jian-Ning Yang, R. Pradhan, L. Rosen, A. Graham +2 more
2014Journal of Clinical Pharmacy and Therapeutics11 citations Open access
Semantic Scholar
Molecular imaging in oncology drug development.
S. Mudd, R. Comley, Mats Bergstrom, K. Holen +5 more
2017Drug Discovery Today10 citations
Semantic Scholar
Abstract 2506: A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors
J. Cleary, L. Yee, N. Azad, M. Carducci +12 more
201210 citations
Semantic Scholar
A phase I study of sorafenib, oxaliplatin and two days of high dose capecitabine in advanced pancreatic and biliary tract cancer: A Wisconsin Oncology Network Study
N. Loconte, K. Holen, W. Schelman, D. Mulkerin +8 more
2012Investigational new drugs10 citations Open access
Semantic Scholar
Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR
W. Munasinghe, R. Mittapalli, Hong Li, David Hoffman +3 more
2017Cancer Chemotherapy and Pharmacology9 citations
Semantic Scholar
ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)
A. Lassman, Cara Dimino, M. Mansukhani, V. Murty +8 more
20179 citations Open access
Semantic Scholar
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer (LARC): Final results of a phase Ib study.
M. Michael, M. Mulcahy, D. Deming, H. Vaghefi +8 more
20159 citations
Semantic Scholar
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
T. Dennie, R. Fleming, C. Bowen, M. Dar +5 more
2011Clinical colorectal cancer9 citations
Semantic Scholar
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance
J. Kolesar, Kamakshi Sachidanandam, W. Schelman, J. Eickhoff +7 more
2010Experimental and Therapeutic Medicine9 citations Open access
Semantic Scholar
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
B. Czito, M. Mulcahy, D. Deming, H. Vaghefi +8 more
20148 citations
Semantic Scholar
A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer
S. Lubner, N. Loconte, K. Holen, W. Schelman +5 more
2010Clinical colorectal cancer8 citations Open access
Semantic Scholar
A Phase I Study of an Oral Simulated FOLFOX with High Dose Capecitabine
D. Mulkerin, N. Loconte, K. Holen, James P. Thomas +7 more
2009Investigational new drugs8 citations Open access
Semantic Scholar
Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer.
S. Lubner, W. Schelman, D. Mulkerin, K. Holen +2 more
20107 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Xiong×15
Invite
H. Xiong — researcher profile on SciRah
N. Loconte×12
Invite
N. Loconte — researcher profile on SciRah
P. Ansell×12
Invite
P. Ansell — researcher profile on SciRah
W. Munasinghe×11
Invite
W. Munasinghe — researcher profile on SciRah

×11

Invite

W. Schelman — researcher profile on SciRah

L. Roberts-Rapp×10

Invite

L. Roberts-Rapp — researcher profile on SciRah

D. Mulkerin×10

Invite

D. Mulkerin — researcher profile on SciRah

Invite

S. Lubner — researcher profile on SciRah

Invite

Gan K. Hui — researcher profile on SciRah

Invite

A. Lassman — researcher profile on SciRah

M. J. van den Bent×8

Invite

M. J. van den Bent — researcher profile on SciRah

P. Kumthekar×8

Invite

P. Kumthekar — researcher profile on SciRah